Health Catalyst (NASDAQ:HCAT – Free Report) had its target price reduced by Wells Fargo & Company from $1.75 to $1.50 in a research report released on Thursday,Benzinga reports. They currently have an equal weight rating on the stock.
A number of other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Health Catalyst in a report on Monday, May 11th. Citigroup lowered their target price on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Weiss Ratings upgraded Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Stephens cut their price target on Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, Canaccord Genuity Group boosted their price objective on Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Health Catalyst has an average rating of “Hold” and a consensus target price of $2.93.
Check Out Our Latest Report on Health Catalyst
Health Catalyst Stock Up 5.7%
Health Catalyst (NASDAQ:HCAT – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. The business had revenue of $70.49 million during the quarter, compared to analyst estimates of $69.09 million. Equities analysts anticipate that Health Catalyst will post -0.25 EPS for the current year.
Institutional Trading of Health Catalyst
Hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in Health Catalyst during the 4th quarter worth $25,000. Visionary Wealth Advisors acquired a new position in shares of Health Catalyst during the second quarter valued at $27,000. Cresset Asset Management LLC bought a new stake in shares of Health Catalyst during the second quarter valued at about $39,000. Deutsche Bank AG bought a new stake in shares of Health Catalyst during the second quarter valued at about $43,000. Finally, Focus Partners Wealth bought a new stake in shares of Health Catalyst during the first quarter valued at about $46,000. Institutional investors own 85.00% of the company’s stock.
About Health Catalyst
Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.
The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.
Read More
- Five stocks we like better than Health Catalyst
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
